EUR 7 Million Grants Boost Trophos Cholesterol-oxime Programs For ALS, MS And Other Neurodegenerative Diseases

Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology, announced that some EUR 7 million in funding has been awarded for two projects associated with its proprietary cholesterol-oxime class of compounds.
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.